Pfizer and BioNTech announced that they had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their investigational BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for further 100 million doses.
Takeda Pharmaceutical announced that it has entered into an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm.
Mylan has agreed to acquire the European thrombosis business from Aspen Pharmacare Holdings for €641.9m.
Catalent and AstraZeneca have signed an agreement under which the former's subsidiary Catalent Cell & Gene Therapy will offer drug substance manufacturing to the investigational Covid-19 vaccine AZD1222 in the US.
Takeda Pharmaceutical has agreed to divest its Japanese consumer healthcare business unit to Blackstone for $2.3bn.
Agilent Technologies has announced an investment of up to $150m to expand its production facility for nucleic acid-based therapeutics in the US.
This edition of the health sciences Journal is about hope and optimism, and how we must rethink our ways of working.
AstraZeneca said that it has closed an agreement with the European Commission (EC) for the supply of up to 400 million doses of the investigational AZD1222 vaccine for the prevention of Covid-19.
Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people.
Pfizer announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for Covid-19.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.